An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)

NCT03202368 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Giant Cell Arteritis

Interventions

DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche